Sort   by:  
 Page size 
RNA-seq of NOMO-1 cell line
ORGANISM(S): Homo sapiens 
Acute myeloid leukemia (AML) and acute T-lymphoblastic leukemia (T-ALL) maintain the undifferentiated phenotype and proliferative capacity of their respective cells of origin, hematopoietic stem/progenitor cells and immature thymocytes. The mechanisms that maintain these progenitor-like characterist...
ORGANISM(S): Homo sapiens 
RNA-seq of NOMO-1 cell line
The project aimed to profile the cell surface proteins of Nomo-1 (AML cell line) using structural surfaceomics for identification of protein conformation-based cancer antigens thereby expanding the toolkit for cancer target discovery for immunotherapeutic targeting. To achieve the goal, cell surface...
ORGANISM(S): Homo sapiens (Human) 
2023-10-04 | PXD035591 | Pride
Transcriptome analysis of NOMO-1 cells with MSLN knockout
The goal was to build a custom proteome database for cell surface proteins of Nomo-1 (AML cell line). Such custom database was meant to facilitate cross-linking (XL-MS) of cell surface proteins for this cell line using non-cleavable cross-linkers. Using such custom database helps with the computatio...
ORGANISM(S): Homo sapiens (Human) 
2023-10-04 | PXD035404 | Pride
The project aimed to profile the cell surface proteins of Nomo-1 (AML cell line) using structural surfaceomics for identification of protein conformation-based cancer antigens thereby expanding the toolkit for cancer target discovery for immunotherapeutic targeting. To achieve the goal, cell surface...
ORGANISM(S): Homo sapiens (Human) 
2023-10-04 | PXD035589 | Pride
MSLN is a newly identified AML target. Because MSLN is not expressed in normal bone marrow specimens, it is an attractive immunotherapy target. However, the function of MSLN in AML is unknown. We generated NOMO-1 cells with CRISPR/CAS9 knockout and performed transcriptome analysis to understand the ...
ORGANISM(S): Homo sapiens 
2026-05-15 | GSE306271 | GEO
RNA-seq in wild-type, METTL16-knockout, and METTL16 rescue NOMO-1 cells
Small molecule inhibitors of the bromodomain and extraterminal (BET) family of proteins are in clinical trials for a variety of cancers, but patient selection strategies are limited. This is due in part to the heterogeneity of response following BET inhibition (BETi), which includes differentiation...
ORGANISM(S): Homo sapiens 
Sort   by:  
 Page size